Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 20/20 | 0.59 |
| ▸ | KDR | P35968 | 20/20 | 0.59 |
| ▸ | MST1R | Q04912 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2670953 | 0.95 | MET (0.61) | METKDRMST1R | |
| SCHEMBL3432950 | 0.93 | MET (0.51) | METKDRMST1R | |
| SCHEMBL1478407 | 0.92 | MET (0.56) | METKDRMST1R | |
| SCHEMBL1674511 | 0.91 | MET (0.53) | METKDRMST1R | |
| SCHEMBL10202332 | 0.88 | MET (0.57) | METKDRMST1R | |
| SCHEMBL3430976 | 0.88 | PDGFRA (0.49) | METKDRMST1R | |
| SCHEMBL1477819 | 0.87 | MET (0.61) | METKDRMST1R | |
| SCHEMBL1674647 | 0.87 | MST1R (0.47) | METKDRMST1R | |
| SCHEMBL2671374 | 0.87 | MET (0.68) | METKDR | |
| SCHEMBL1674713 | 0.85 | MET (0.49) | METKDRMST1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140179632-A1 | METHODS OF INHIBITING PROTEIN TYROSINE KINASE ACTIVITY | METHYLGENE INC. (CA) | 2014-06-26 | — | — | US | disclosed |
| US-8729268-B2 | Inhibitors of protein tyrosine kinase activity | METHYLGENE INC. (CA) | 2014-05-20 | — | — | US | disclosed |
| EP-2332536-A1 | Inhibitors of protein tyrosine kinase activity | MethylGene Inc. (CA) | 2011-06-15 | — | — | EP | disclosed |
| US-20110098293-A1 | Inhibitors of Protein Tyrosine Kinase Activity | OTSUKA PHARMACEUTICAL CO. LTD. (JP) | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179632-A1 | METHODS OF INHIBITING PROTEIN TYROSINE KINASE ACTIVITY | PTK2B, PRKACA, DSTYK | MET 240/4885KDR 70/4885MST1R 285/4885 |
| US-20110098293-A1 | Inhibitors of Protein Tyrosine Kinase Activity | ABL1, ERBB2, TYRO3 | MET 111/4885KDR 8/4885MST1R 136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.